Celon Pharma Future Growth
Future criteria checks 4/6
Celon Pharma is forecast to grow earnings and revenue by 78.7% and 6.4% per annum respectively. EPS is expected to grow by 125% per annum. Return on equity is forecast to be 2.8% in 3 years.
Key information
78.7%
Earnings growth rate
125.0%
EPS growth rate
| Pharmaceuticals earnings growth | 14.3% |
| Revenue growth rate | 6.4% |
| Future return on equity | 2.8% |
| Analyst coverage | Low |
| Last updated | 25 Apr 2024 |
Recent future growth updates
Recent updates
Earnings Update: Celon Pharma S.A. (WSE:CLN) Just Reported And Analysts Are Boosting Their Estimates
Sep 24
Celon Pharma (WSE:CLN) Is In A Good Position To Deliver On Growth Plans
Jul 13We're Interested To See How Celon Pharma (WSE:CLN) Uses Its Cash Hoard To Grow
Nov 04We Think Celon Pharma (WSE:CLN) Can Afford To Drive Business Growth
Aug 04Celon Pharma (WSE:CLN) Seems To Use Debt Quite Sensibly
May 23Calculating The Intrinsic Value Of Celon Pharma S.A. (WSE:CLN)
Mar 02Celon Pharma S.A. (WSE:CLN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Feb 09
Celon Pharma's (WSE:CLN) Earnings Are Growing But Is There More To The Story?
Jan 20Celon Pharma (WSE:CLN) Shareholders Have Enjoyed A 12% Share Price Gain
Dec 24Celon Pharma (WSE:CLN) Has A Pretty Healthy Balance Sheet
Dec 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 305 | 31 | 41 | 104 | 1 |
| 12/31/2025 | 274 | -3 | 23 | 44 | 4 |
| 12/31/2024 | 249 | -20 | 18 | 28 | 4 |
| 12/31/2023 | 217 | -28 | -41 | -8 | N/A |
| 9/30/2023 | 214 | -25 | -31 | 7 | N/A |
| 6/30/2023 | 211 | -30 | -53 | -16 | N/A |
| 3/31/2023 | 196 | -47 | -42 | -8 | N/A |
| 12/31/2022 | 194 | -39 | -39 | -5 | N/A |
| 9/30/2022 | 191 | -31 | -39 | -10 | N/A |
| 6/30/2022 | 186 | -28 | -11 | 32 | N/A |
| 3/31/2022 | 191 | -17 | -17 | 25 | N/A |
| 12/31/2021 | 196 | -12 | 3 | 44 | N/A |
| 9/30/2021 | 186 | -11 | 7 | 60 | N/A |
| 6/30/2021 | 185 | -2 | 3 | 57 | N/A |
| 3/31/2021 | 170 | 0 | -18 | 71 | N/A |
| 12/31/2020 | 157 | -1 | -28 | 72 | N/A |
| 9/30/2020 | 142 | 4 | -58 | 37 | N/A |
| 6/30/2020 | 128 | 5 | -88 | 6 | N/A |
| 3/31/2020 | 109 | 3 | -85 | -19 | N/A |
| 12/31/2019 | 102 | 12 | -70 | -5 | N/A |
| 9/30/2019 | 110 | 17 | -69 | 6 | N/A |
| 6/30/2019 | 118 | 23 | -61 | 15 | N/A |
| 3/31/2019 | 124 | 29 | -31 | 37 | N/A |
| 12/31/2018 | 125 | 30 | -39 | 28 | N/A |
| 9/30/2018 | 116 | 30 | -30 | 27 | N/A |
| 6/30/2018 | 109 | 26 | -8 | 34 | N/A |
| 3/31/2018 | 107 | 28 | -16 | 26 | N/A |
| 12/31/2017 | 107 | 26 | -6 | 25 | N/A |
| 9/30/2017 | 129 | 22 | N/A | 18 | N/A |
| 6/30/2017 | 127 | 24 | N/A | 23 | N/A |
| 3/31/2017 | 115 | 27 | N/A | 28 | N/A |
| 12/31/2016 | 129 | 38 | N/A | 21 | N/A |
| 9/30/2016 | 111 | 42 | N/A | 34 | N/A |
| 12/31/2015 | 108 | 37 | N/A | 52 | N/A |
| 12/31/2014 | 98 | 52 | N/A | 24 | N/A |
| 12/31/2013 | 72 | 18 | N/A | 8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.6%).
Earnings vs Market: CLN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CLN is expected to become profitable in the next 3 years.
Revenue vs Market: CLN's revenue (6.4% per year) is forecast to grow faster than the Polish market (4.2% per year).
High Growth Revenue: CLN's revenue (6.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CLN's Return on Equity is forecast to be low in 3 years time (2.8%).